Precigen amends exclusive license agreement with Alaunos Therapeutics

Precigen (PGEN) announced the amendment of its exclusive license agreement with Alaunos Therapeutics (TCRT). With this amendment, Precigen has the unique ability to utilize the clinically validated UltraCAR-T platform for unencumbered development and commercialization of two proven CAR-T targets, CD19 and B-cell maturation antigen. These targets enhance Precigen’s UltraCAR-T library approach, which is designed to transform the personalized cell therapy landscape for cancer patients through the development and validation of a library of non-viral plasmids to target various hematological and solid tumor-associated antigens. Enabled by the design and manufacturing advantages of UltraCAR-T, coupled with the capabilities of the UltraPorator system, Precigen is working to empower cancer centers to deliver personalized, autologous CAR-T treatment with overnight manufacturing for cancer patients. The addition of CD19 and BCMA targets positions Precigen as a front runner in the CAR-T space. Precigen also regained exclusive rights to its interleukin-12 gene therapy, including application through the off-the-shelf AdenoVerse immunotherapy platform, paving the way for potential future treatments in oncology given the important role of IL-12 cytokines in targeting many types of tumors such as HPV-associated cancers. Precigen maintains the right to pursue non-neoantigen T-cell receptors. As part of the amendment, all milestone payments and royalties between the parties have been eliminated.